FDA Sent 25 Telehealth Companies the Same Letter on the Same Day. The Violation Was Their Website Copy.

On June 8, 2026, FDA issued 25 warning letters to telehealth companies selling compounded semaglutide and tirzepatide. They posted publicly the week of June 16. Every letter came from the Center for Drug Evaluation and Research. Every one directs the response to the Office of Compounding Quality and Compliance.

The notable thing is not the volume. It is the method. No inspection took place. FDA staff read the companies' websites, in most cases in March 2026, and built the entire enforcement action out of marketing copy.

If you sell a compounded drug product and you have a website, this is the most operationally relevant enforcement pattern of the quarter.

Who received letters

Twenty-five companies, all on June 8:

Altru Telehealth · Amie Health · Clover Meds · D&H Medical Services · Eden Health International (Eden) · Ezra Holdco (Ezra) · FITISH · FitRX (AM RX) · Glow Medispa (Mint Med) · HydraMed IV · Joi and Blokes · Maximus Health (Maximus) · Medica Weight Loss · Momentum Health 360 · NativeMed · Nexlife · Nexus Health Solutions (Harper Meds) · Nova Vascular (NOVARX) · OrderlyMeds · Public Health Solution (DrMedHealth) · Ready Med · Roen Health (RoenRx) · Thrivelab · Trinity HealthCare Supply (altRx) · VivioMD Group

The list spans venture-backed consumer health brands and small regional med spas. Size offered no protection in either direction.

The statute FDA reached for

Most misbranding actions cite section 502(a) of the FD&C Act — labeling that is false or misleading. These letters cite 502(a) and 502(bb).

Section 502(bb) [21 U.S.C. § 352(bb)] is specific to compounded drugs, and it extends misbranding to advertising and promotion, not just labeling. That is the hinge. Under 502(a) alone, FDA argues about what is on the product. Under 502(bb), FDA can treat your homepage as the violation.

The consequence chain in the letters runs: false or misleading promotion → product is misbranded under 502(a) and 502(bb) → introducing it into interstate commerce is a prohibited act under section 301(a) [21 U.S.C. § 331(a)]. The letters also note that receiving misbranded drugs in interstate commerce and delivering them violates section 301(c).

The two claims that generated most of the letters

Reading the Eden Health letter (MARCS-CMS 728279) against the others, two specific representations do the bulk of the work.

1. Putting your own brand on a label for a drug you did not compound.

FDA's finding, on Eden's product imagery:

"The compounded semaglutide and tirzepatide products displayed on your website identify 'Eden' on the pictured label, suggesting Eden is the compounder of those drugs when in fact it is not."

This one catches almost every direct-to-consumer telehealth brand, because private-label presentation is the default in consumer health design. The vial in the hero image carries the brand the customer bought from. FDA's position is that this misrepresents who made the drug.

2. Calling a compounder "FDA-licensed" or "FDA-approved."

Eden's site claimed its products were sourced from "FDA-licensed 503(a) outsourcing facilities." FDA's response:

"Compounding facilities, including pharmacies and outsourcing facilities, are not 'FDA-approved' or 'FDA-licensed' entities. The FD&C Act does not establish an 'FDA-approved' or 'FDA-licensed' designation for pharmacies or outsourcing facilities."

That phrase contains a second error worth flagging separately, because it is extremely common: "503(a) outsourcing facility" is not a thing. Section 503A covers compounding pharmacies. Section 503B covers outsourcing facilities, which do register with FDA. Merging the two into one impressive-sounding phrase produces a claim that is wrong twice over.

Our reading of the pattern

Three inferences, flagged as interpretation rather than fact:

This is cheap enforcement, so expect more of it. A website review requires no travel, no investigator time on site, and no 483. FDA assigned Establishment Identifiers to websites and reviewed 25 of them in a single month. Nothing about that workflow caps at 25.

The target is the marketing layer, not the compounding layer. These letters do not allege that anyone's semaglutide was contaminated, sub-potent, or improperly compounded. They allege the companies described it inaccurately. That is a different — and much easier — case for FDA to make.

The remediation ask hints at the next step. FDA asked recipients to identify "the entities that produce the compounded drug products offered on your website" and to supply representative labeling. FDA is mapping the supply chain behind the storefronts. Our reading: the compounders themselves are a plausible next cohort. We have not seen letters to them yet, and we are not predicting a timeline.

The letters also restate, pointedly, that compounded products must meet the conditions of section 503A or 503B to be exempt from the new drug approval requirements. That sentence is doing quiet work — it is a reminder that the underlying exemption is conditional.

What to do this week

If you market a compounded drug product — GLP-1 or otherwise:

1. Audit every product image. If a vial, pen, or box in your marketing shows your brand and you did not compound it, fix the image or add unambiguous attribution to the actual compounder.
2. Search your entire site for "FDA." Every instance. "FDA-approved," "FDA-licensed," "FDA-registered," "FDA-cleared" attached to a pharmacy, an outsourcing facility, or a compounded product is a defect. Registration with FDA is a fact you may state plainly; approval and licensure are not things FDA grants to these entities.
3. Fix "503(a) outsourcing facility" wherever it appears. Pharmacies are 503A. Outsourcing facilities are 503B.
4. Check your affiliate and paid-ad copy too. 502(bb) reaches promotion, and the letters were built from public-facing material. Ad copy you did not write but do benefit from is worth reviewing.
5. Recipients have 15 business days to respond to compoundinginspections@fda.hhs.gov.

If you sell only FDA-approved finished drugs: 502(bb) does not apply to you, and no action is required on this basis. 502(a) still governs your labeling.

The broader point

The compliance failure here was not manufacturing. It was copywriting — specifically, marketing language written to build consumer trust that happened to describe a regulatory status that does not exist. "FDA-licensed" reads as reassuring. It is also, as of June 8, documented grounds for a warning letter.

Twenty-five companies used essentially the same phrasing because it is the phrasing the category converged on. That is worth sitting with. If your competitors' websites are where your compliance copy comes from, you inherit their violations.

Sources

• FDA Warning Letters issued June 8, 2026, posted week of June 16, 2026, Center for Drug Evaluation and Research — FDA Warning Letters database
• Eden Health International Inc. dba Eden, MARCS-CMS 728279
• FD&C Act sections 502(a), 502(bb), 301(a), 301(c), 503A, 503B [21 U.S.C. §§ 352(a), 352(bb), 331(a), 331(c), 353a, 353b]

Policy Canary tracks FDA enforcement and matches it against your specific products. We are an intelligence service, not a law firm — this is analysis, not legal advice.